Posts filed under ‘Resistencia bacteriana’

Pseudomonas aeruginosa Eradication: How Do We Measure Success?

Clinical Infectious Diseases SEP 1, 2015 V.61 N.5 P.716-718

Editorial Commentary

Edith T. Zemanick and Theresa A. Laguna

1Department of Pediatrics, University of Colorado School of Medicine, Aurora

2Department of Pediatrics, University of Minnesota School of Medicine, Minneapolis

Correspondence: Edith T. Zemanick, MD, MSCS, Department of Pediatrics, University of Colorado School of Medicine, 13123 E 16th Ave B-395, Aurora, CO 80045 (

Lung disease remains the major cause of morbidity and mortality for people living with cystic fibrosis (CF) [1].

Dysfunctional chloride conductance in the airways results in impaired mucus clearance, which drives a vicious cycle of infection, inflammation, and airway destruction.

Pseudomonas aeruginosa (Pa) is a bacterial pathogen largely feared by the CF community as its chronic presence is associated with lung damage, a more rapid decline in lung function, and earlier mortality [2–6]. Unfortunately, Pa in airway secretions will be cultured in 80% of people with CF by age 18 years.


August 29, 2015 at 7:36 pm

Population Structure and Antimicrobial Resistance of Invasive Serotype IV Group B Streptococcus, Toronto, Ontario, Canada

Emerging Infectious Diseases MAY 2015 V.21 N.4


Sarah Teatero, Allison McGeer, Aimin Li, Janice Gomes, Christine Seah, Walter Demczuk, Irene Martin, Jessica Wasserscheid, Ken Dewar, Roberto G. Melano, and Nahuel Fittipaldi

Public Health Ontario, Toronto, Ontario, Canada (S. Teatero, A. Li, J. Gomes, C. Seah, R.G. Melano, N. Fittipaldi); University of Toronto, Toronto (A. McGeer, R.G. Melano, N. Fittipaldi); Mount Sinai Hospital, Toronto (A. McGeer, R.G. Melano); Public Health Agency of Canada, Winnipeg, Manitoba, Canada (W. Demczuk, I. Martin); McGill University, Montreal, Quebec, Canada (J. Wasserscheid, K. Dewar); Genome Quebec Innovation Centre, Montreal (J. Wasserscheid, K. Dewar)

We recently showed that 37/600 (6.2%) invasive infections with group B Streptococcus (GBS) in Toronto, Ontario, Canada, were caused by serotype IV strains.

We report a relatively high level of genetic diversity in 37 invasive strains of this emerging GBS serotype. Multilocus sequence typing identified 6 sequence types (STs) that belonged to 3 clonal complexes.

Most isolates were ST-459 (19/37, 51%) and ST-452 (11/37, 30%), but we also identified ST-291, ST-3, ST-196, and a novel ST-682.

We detected further diversity by performing whole-genome single-nucleotide polymorphism analysis and found evidence of recombination events contributing to variation in some serotype IV GBS strains.

We also evaluated antimicrobial drug resistance and found that ST-459 strains were resistant to clindamycin and erythromycin, whereas strains of other STs were, for the most part, susceptible to these antimicrobial drugs.


August 29, 2015 at 11:05 am

KPC and NDM-1 Genes in Related Enterobacteriaceae Strains and Plasmids from Pakistan and the United States

Emerging Infectious Diseases Jun 2015 V.21 N.6


Mitchell W. Pesesky1, Tahir Hussain1, Meghan Wallace, Bin Wang, Saadia Andleeb, Carey-Ann D. Burnham, and Gautam Dantas

Washington University School of Medicine in St. Louis, St. Louis, Missouri, USA (M.W. Pesesky, T. Hussain. M. Wallace, B. Wang, C.D. Burnham, G. Dantas); National University of Sciences and Technology, Islamabad, Pakistan (T. Hussain, S. Andleeb)

To characterize the genomic context of New Delhi metallo-β-lactamase-1 (NDM-1) and Klebsiella pneumoniae carbapenemase (KPC), we sequenced 78 Enterobacteriaceae isolates from Pakistan and the United States encoding KPC, NDM-1, or no carbapenemase.

High similarities of the results indicate rapid spread of carbapenem resistance between strains, including globally disseminated pathogens.


August 28, 2015 at 8:21 am

Extensively Drug-Resistant New Delhi Metallo-β-Lactamase–Encoding Bacteria in the Environment, Dhaka, Bangladesh, 2012

Emerging Infectious Diseases Jun 2015 V.21 N.6


Mark A. Toleman, Joachim J. Bugert, and Syed A. Nizam

Cardiff University, Heath Park Campus, Cardiff, Wales, UK

Carriage of the New Delhi metallo-β-lactamase variant 1 (NDM-1) enables drug resistance to move between communities and hospitals.

In Bangladesh, we found the blaNDM-1 gene in 62% of environmental waters and in fermentative and nonfermentative gram-negative bacteria.

Escherichia coli sequence type (ST) 101 was most commonly found, reflecting a common global relationship between ST101 and NDM-1.



August 28, 2015 at 8:19 am

Macrolide-Resistant Mycoplasma pneumoniae, United State

Emerging Infectious Diseases Aug 2015 V.21 N.8

Xiaotian ZhengComments to Author , Stella Lee, Rangaraj Selvarangan, Xuan Qin, Yi-Wei Tang, Jeffrey Stiles, Tao Hong, Kathleen Todd, Amy E. Ratliff, Donna M. Crabb, Li Xiao, T. Prescott Atkinson, and Ken B. Waites

Ann & Robert H. Lurie Children’s Hospital of Chicago, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA (X. Zheng, S. Lee, K. Todd); The Children’s Mercy Hospitals and Clinics, Kansas City, Missouri, USA (R. Selvarangan); Seattle Children’s Hospital, Seattle, Washington, USA (X. Qin); Memorial Sloan-Kettering Cancer Center and Weill Medical College of Cornell University, New York, New York, USA (Y.W. Tang, J. Stiles); Hackensack University Medical Center, Hackensack, New Jersey, USA (T. Hong); University of Alabama at Birmingham, Birmingham, Alabama, USA (A.E. Ratliff, D.M. Crabb, L. Xiao, T.P. Atkinson, K.B. Waites)

Macrolide-resistant Mycoplasma pneumoniae (MRMP) is highly prevalent in Asia and is now being reported from Europe.

Few data on MRMP are available in the United States.

Using genotypic and phenotypic methods, we detected high-level MRMP in 13.2% of 91 M. pneumoniae­–positive specimens from 6 US locations.


August 28, 2015 at 8:16 am

Emerging Infections Program as Surveillance for Antimicrobial Drug Resistance

Emerging Infectious Diseases Sept 2015 V.21 N.9

Scott K. Fridkin, Angela A. Cleveland, Isaac See, and Ruth Lynfield

Centers for Disease Control and Prevention, Atlanta, Georgia, USA (S.K. Fridkin, A.A. Cleveland, I. See); Minnesota Department of Public Health, St. Paul, Minnesota, USA (R. Lynfield)

Across the United States, antimicrobial drug–resistant infections affect a diverse population, and effective interventions require concerted efforts across various public health and clinical programs.

Since its onset in 1994, the Centers for Disease Control and Prevention Emerging Infections Program has provided robust and timely data on antimicrobial drug–resistant infections that have been used to inform public health action across a spectrum of partners with regard to many highly visible antimicrobial drug–resistance threats.

These data span several activities within the Program, including respiratory bacterial infections, health care–associated infections, and some aspects of foodborne diseases.

These data have contributed to estimates of national burden, identified populations at risk, and determined microbiological causes of infection and their outcomes, all of which have been used to inform national policy and guidelines to prevent antimicrobial drug–resistant infections.


August 28, 2015 at 8:14 am

Improved Phenotype-Based Definition for Identifying Carbapenemase Producers among Carbapenem-Resistant Enterobacteriaceae

Emerging Infectious Diseases Sept 2015 V.21 N.9

Emerging Infections Program

Nora Chea, Sandra N. Bulens, Thiphasone Kongphet-Tran, Ruth Lynfield, Kristin M. Shaw, Paula Snippes Vagnone, Marion A. Kainer, Daniel B. Muleta, Lucy Wilson, Elisabeth Vaeth, Ghinwa Dumyati, Cathleen Concannon, Erin C. Phipps, Karissa Culbreath, Sarah J. Janelle, Wendy M. Bamberg, Alice Y. Guh, Brandi Limbago, and Alexander J. Kallen

Centers for Disease Control and Prevention, Atlanta, Georgia, USA (N. Chea, S.N. Bulens, T. Kongphet-Tran, A.Y. Guh, B. Limbago, A.J. Kallen); Minnesota Department of Health, St. Paul, Minnesota, USA (R. Lynfield, K.M. Shaw, P. Snippes Vagnone); Tennessee Department of Health, Nashville, Tennessee, USA (M.A Kainer, D.B. Muleta); Maryland Emerging Infections Program, Baltimore, Maryland, USA (L. Wilson, E. Vaeth); New York–Rochester Emerging Infections Program, Rochester, New York, USA (G. Dumyati, C. Concannon); University of Rochester Medical Center, Rochester (G. Dumyati, C. Concannon); University of New Mexico, Albuquerque, New Mexico, USA (E.C. Phipps, K. Culbreath); Colorado Department of Public Health and Environment, Denver, Colorado, USA (S.J. Janelle, W.M. Bamberg)

Preventing transmission of carbapenemase-producing, carbapenem-resistant Enterobacteriaceae (CP-CRE) is a public health priority. A phenotype-based definition that reliably identifies CP-CRE while minimizing misclassification of non–CP-CRE could help prevention efforts.

To assess possible definitions, we evaluated enterobacterial isolates that had been tested and deemed nonsusceptible to >1 carbapenem at US Emerging Infections Program sites.

We determined the number of non-CP isolates that met (false positives) and CP isolates that did not meet (false negatives) the Centers for Disease Control and Prevention CRE definition in use during our study: 30% (94/312) of CRE had carbapenemase genes, and 21% (14/67) of Klebsiella pneumoniae carbapenemase–producing Klebsiella isolates had been misclassified as non-CP.

A new definition requiring resistance to 1 carbapenem rarely missed CP strains, but 55% of results were false positive; adding the modified Hodge test to the definition decreased false positives to 12%. This definition should be considered for use in carbapenemase-producing CRE surveillance and prevention.


August 28, 2015 at 8:13 am

Older Posts


August 2015
« Jul    

Posts by Month

Posts by Category


Get every new post delivered to your Inbox.

Join 85 other followers